mAbxience | News

Publication of the final data from the clinical trial for mAbxience bevacizumab in metastatic colorectal cancer published in The Lancet Gastroenterology & Hepatology

09/27/2018

The prestigious scientific journal The Lancet Gastroenterology and Hepatology journal has published the results of the comparative study of pharmacokinetics, efficacy, safety and immunogenicity of bevacizumab biosimilar BEVZ92 in combination with FOLFOX or FOLFIRI, as the first-line treatment for metastatic colorectal cancer versus the original reference product.  The trial included 15 sites from 5 countries, […]

Insud Pharma secures “very good” rating in the Profarma Programme

09/24/2018

mAbxience and the entire Insud Pharma group have once again been rated “very good” in the 2017-2020 edition of the Spanish government’s Profarma Programme, thanks to our contribution to modernising the sector, our commitment to R&D and our clear focus on activities that add value. The Programme is run by the Spanish Ministry of Economy, […]

The Autonomous University of Madrid and Insud Pharma 
join forces for biomedical innovation

07/16/2018

The Autonomous University of Madrid (UAM) and the multinational pharmaceutical company Insud Pharma are launching the UAM-Insud Pharma Programme of Innovation Challenges with a Strong Social Impact for biomedical innovation with an open innovation approach that enables the transfer of knowledge through science excellence to overcome some of the specific challenges of our society. This […]

mAbxience and Amneal enter into an agreement for bevacizumab biosimilar in the United States

05/23/2018

The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment.

Biosimilars reduce healthcare costs by up to 40% and increase patient accessibility to innovative treatments

05/07/2018

These medicinal products are similar to their counterparts in terms of efficacy, safety and quality, and are backed by comprehensive clinical studies Cancer treatments are some of the ones that benefit the most from this medical innovation, and at a lower price for Health Authorities Treatments with biosimilar medicinal products mean that more patients are […]

5th Castilla y León’s Best Director Awards

04/30/2018

On the occasion of the awards granted by Castilla y León Económica magazine for the fifth year, Luisa Amoedo, director of mAbxience León, has been awarded as Best Export / Internationalization Director. The jury of the 5th Castilla y León’s Best Director Awards is composed of José María Ribot García, General Manager of Instituto para […]

Cancer Chemotherapy and Pharmacology has published comparative data of rituximab biosimilar RTXM83R in lymphoma patients

03/06/2018

The journnal Cancer Chemotherapy and Pharmacology has recently published the randomized, double-blind, phase III and comparative clinical study of pharmacokinetics and pharmacodynamics between RTXM83™ rituximab biosimilar and its reference product in diffuse large B-cell lymphoma patients.  The main objective was to quantify any potential differences in pharmacokinetic (PK) parameters (AUC and Cmax). To demonstrate biosimilarity […]

2nd National Conference on Biosimilars

03/05/2018

mAbxience actively participated in the 2nd National Conference on Biosimilars organised by the Spanish Biosimilar Medicines Association, BioSim. The conference, entitled “Biosimilars: evidence and efficiency”, took place at the Ministry of Health, Social Services and Equality in Madrid on 21st February. Francisco Olivera, Operations Manager at mAbxience León, shared the “Evidence: from R&D to authorisation” […]

INSUD PHARMA is the new name of Chemo Group

11/24/2017

Therefore, our three pharma brands, Chemo, Exeltis and mAbxience, are now grouped together under this name. This new identity is the result of the development and diversification of the company’s pharma activity. Madrid, 24 November 2017–From now on, Chemo Group, the pharmaceutical multinational that is present in over 40 countries, is going to be called […]

mAbxience analyses getting a new plant in Argentina

07/31/2017

The company is part of the multinational CHEMO group, with 40 years’ experience in the pharmaceutical industry and presence in more than 40 countries. The biotechnology company dedicated to the R&D, manufacture and commercialisation of drugs, mainly biosimilars medicines, already has an R&D centre in Spain, together with a monoclonal antibody production plant in Munro, […]